{"id":9186,"date":"2024-09-05T08:34:01","date_gmt":"2024-09-05T15:34:01","guid":{"rendered":"https:\/\/www.breakthrought1d.org\/pacificnorthwest\/?p=9186"},"modified":"2026-05-21T16:40:38","modified_gmt":"2026-05-21T16:40:38","slug":"novel-interventions-for-t1d-complications","status":"publish","type":"post","link":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/","title":{"rendered":"Novel Interventions for T1D Complications"},"content":{"rendered":"<p>People living with T1D are at higher risk for long-term <a href=\"https:\/\/www.breakthrought1d.org\/t1d-resources\/complications\/\">complications<\/a> affecting the heart and cardiovascular system, eyes, kidneys and peripheral nerves. Ongoing <a href=\"https:\/\/www.breakthrought1d.org\/explore-research\/\">T1D research<\/a> recognizes the need for more options for treating or preventing these complications within the T1D population. Rainier Clinical Research Center in Seattle is currently recruiting for two such studies:<\/p>\n<h2><em><strong>Merck Cholesterol Study:<\/strong><\/em><\/h2>\n<p>This study is evaluating the efficacy and safety of an investigational drug MK-0616, compared with ezetimibe, bempedoic acid, or the combination of ezetimibe + bempedoic acid in adults with high cholesterol. MK-0616 reduces cholesterol by increasing the clearance of cholesterol particles (specifically LDL particles) from the blood. MK-0616 is an oral version of PSCK9 inhibitor injectables. Injectable PSCK9 inhibitors are already FDA-approved for the treatment of high cholesterol in people with known cardiovascular disease or with a genetic form of hypercholesterolemia.<\/p>\n<p>Rainier Clinical Research Center is looking for volunteers with high cholesterol, who also have cardiovascular disease or are at high risk for cardiovascular disease. Adults with high cholesterol and <a href=\"https:\/\/www.breakthrought1d.org\/t1d-basics\/\">type 1 diabetes<\/a> are at higher risk of cardiovascular disease and potentially would qualify. Participants must also be taking a statin medication.<\/p>\n<p>This study will last 5 months with 5 in-person visits. Compensation is $650 for study completion.<\/p>\n<h2><strong>LXBD\/ Diabetic Peripheral Neuropathy:<\/strong><\/h2>\n<p>This study will be evaluating the efficacy of investigational drug LY3556050 compared to placebo in reducing the pain associated with diabetic peripheral neuropathy. LY3556050 is a novel drug that reduces pain by interrupting the transmission of pain signals along sensory nerves to the brain. LY3556050 is an oral medication.<\/p>\n<p>Rainier Clinical Research Center is looking for individuals with type 1 or type 2 diabetes who have been diagnosed with diabetic peripheral neuropathy for at least 6 months.<\/p>\n<p>This study will last up to 24 weeks and includes 9 in-person visits. Participants will be compensated up to $1,830 for study completion.<\/p>\n<p>If you are interested in these studies, please contact Rainier Clinical Research Center at <a href=\"mailto:recruitment@rainier-research.com\">recruitment@rainier-research.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>People living with T1D are at higher risk for long-term complications affecting the heart and cardiovascular system, eyes, kidneys and peripheral nerves. Ongoing T1D research recognizes the need for more options for treating or preventing these complications within the T1D&hellip;<\/p>\n","protected":false},"author":1317,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"publish_on_app_meta":"True","iawp_total_views":4,"footnotes":"","_members_access_role":[],"_members_access_error":"","bt1d_storytelling_post":false,"bt1d_storytelling_more_posts":[]},"topics":[31],"class_list":["post-9186","post","type-post","status-publish","format-standard","hentry","jdrf_topic-clinical-trials"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>T1D Complications Trials | Breakthrough T1D Greater Northwest<\/title>\n<meta name=\"description\" content=\"Rainier Clinical Research Center is recruiting for two diabetes complications studies in Seattle. Learn about the Merck cholesterol trial (MK-0616) and the oral neuropathic pain relief study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"T1D Complications Trials | Breakthrough T1D Greater Northwest\" \/>\n<meta property=\"og:description\" content=\"Rainier Clinical Research Center is recruiting for two diabetes complications studies in Seattle. Learn about the Merck cholesterol trial (MK-0616) and the oral neuropathic pain relief study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Northwest Chapter\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/breakthrought1dHQ\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-05T15:34:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T16:40:38+00:00\" \/>\n<meta name=\"author\" content=\"Breakthrough T1D Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:site\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Breakthrough T1D Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/\"},\"author\":{\"name\":\"Breakthrough T1D Author\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/person\\\/d91bebaf8f6259d18f7a0d24d101e6e6\"},\"headline\":\"Novel Interventions for T1D Complications\",\"datePublished\":\"2024-09-05T15:34:01+00:00\",\"dateModified\":\"2026-05-21T16:40:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/\"},\"wordCount\":324,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/\",\"name\":\"T1D Complications Trials | Breakthrough T1D Greater Northwest\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#website\"},\"datePublished\":\"2024-09-05T15:34:01+00:00\",\"dateModified\":\"2026-05-21T16:40:38+00:00\",\"description\":\"Rainier Clinical Research Center is recruiting for two diabetes complications studies in Seattle. Learn about the Merck cholesterol trial (MK-0616) and the oral neuropathic pain relief study.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2024\\\/09\\\/05\\\/novel-interventions-for-t1d-complications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novel Interventions for T1D Complications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#website\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\",\"name\":\"Greater Northwest Chapter\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"contentUrl\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"width\":400,\"height\":400,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/breakthrought1dHQ\",\"https:\\\/\\\/x.com\\\/breakthrought1d\",\"https:\\\/\\\/www.youtube.com\\\/@breakthrought1d\",\"https:\\\/\\\/www.instagram.com\\\/breakthrought1d\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@breakthrought1dhq\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/person\\\/d91bebaf8f6259d18f7a0d24d101e6e6\",\"name\":\"Breakthrough T1D Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"caption\":\"Breakthrough T1D Author\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"T1D Complications Trials | Breakthrough T1D Greater Northwest","description":"Rainier Clinical Research Center is recruiting for two diabetes complications studies in Seattle. Learn about the Merck cholesterol trial (MK-0616) and the oral neuropathic pain relief study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/","og_locale":"en_US","og_type":"article","og_title":"T1D Complications Trials | Breakthrough T1D Greater Northwest","og_description":"Rainier Clinical Research Center is recruiting for two diabetes complications studies in Seattle. Learn about the Merck cholesterol trial (MK-0616) and the oral neuropathic pain relief study.","og_url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/","og_site_name":"Greater Northwest Chapter","article_publisher":"https:\/\/www.facebook.com\/breakthrought1dHQ","article_published_time":"2024-09-05T15:34:01+00:00","article_modified_time":"2026-05-21T16:40:38+00:00","author":"Breakthrough T1D Author","twitter_card":"summary_large_image","twitter_creator":"@breakthrought1d","twitter_site":"@breakthrought1d","twitter_misc":{"Written by":"Breakthrough T1D Author","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/#article","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/"},"author":{"name":"Breakthrough T1D Author","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6"},"headline":"Novel Interventions for T1D Complications","datePublished":"2024-09-05T15:34:01+00:00","dateModified":"2026-05-21T16:40:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/"},"wordCount":324,"commentCount":0,"publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/","name":"T1D Complications Trials | Breakthrough T1D Greater Northwest","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website"},"datePublished":"2024-09-05T15:34:01+00:00","dateModified":"2026-05-21T16:40:38+00:00","description":"Rainier Clinical Research Center is recruiting for two diabetes complications studies in Seattle. Learn about the Merck cholesterol trial (MK-0616) and the oral neuropathic pain relief study.","breadcrumb":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2024\/09\/05\/novel-interventions-for-t1d-complications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/"},{"@type":"ListItem","position":2,"name":"Novel Interventions for T1D Complications"}]},{"@type":"WebSite","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","name":"Greater Northwest Chapter","description":"","publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization","name":"Breakthrough T1D","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","width":400,"height":400,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/breakthrought1dHQ","https:\/\/x.com\/breakthrought1d","https:\/\/www.youtube.com\/@breakthrought1d","https:\/\/www.instagram.com\/breakthrought1d\/","https:\/\/www.tiktok.com\/@breakthrought1dhq"]},{"@type":"Person","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6","name":"Breakthrough T1D Author","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","caption":"Breakthrough T1D Author"}}]}},"_links":{"self":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/9186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/users\/1317"}],"replies":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/comments?post=9186"}],"version-history":[{"count":0,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/9186\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/media?parent=9186"}],"wp:term":[{"taxonomy":"jdrf_topic","embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/topics?post=9186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}